Sexual and reproductive health
Melanotan-1 (MT-1)
Also called Melanotan I, MT-1, MT1, Afamelanotide
per administration
It has been used in people, but no trial has settled how much or how often.
Licensed as a medicine in the US and EU as a 16 mg implant, not as an injection.
The human evidence for Melanotan-1 (MT-1) used the implant route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
Melanotan-1 (MT-1) at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 250–1000 mcg per administration
- How often
- Every day
- Where
- Subcutaneous implant Sites and rotation
- Time to steady level
- ~5 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C78H111N21O19
- Mol. weight
- 1,646.8 Da
- CAS
- 75921-69-6
- PubChem CID
- 16197727
External references
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Melanotan-1 (MT-1) describe 250–1000 mcg per administration. Descriptive only, not a recommendation.
About an hour for the free peptide. The licensed form is a slow-release implant with completely different kinetics, so implant figures do not transfer to this curve.
The licensed form is a 16 mg controlled-release implant, whose figures do not carry over to an injection; no injected schedule is established, so no schedule table is shown.
What it can be combined with
How Melanotan-1 (MT-1) is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- PT-141Both are melanocortin-receptor agonists, so together they compound the same effects, including nausea.Use caution
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 5hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Afamelanotide (licensed implant) literatureThe licensed form is a slow-release implant; injectable free-peptide schedules are community-derived.